Nicox – executive interview

Nicox develops therapeutics for eye diseases, with lead candidate NCX-470 in Phase III development for the topical ocular treatment of glaucoma. NCX-470 combines a Nitric oxide-donating molecule with an analogue of established prostaglandin F2a drug, bimatoprost. NCX-470 showed non-inferiority to latanoprost in the Mont Blanc pivotal study and a second Phase III study, Denali, is underway. Nicox is also advancing NCX-4251 for dry eye disease and preclinical-stage NCX-1728 for retinal diseases. Nicox receives licence revenue for its FDA-approved drugs, Vyzulta and Zerviate.

In this interview, Andreas Segerros, chief executive officer of Nicox, describes his prior experiences of bringing a leading glaucoma drug to market and what attracted him to join Nicox and help advance its product development pipeline. He outlines the positive results from the recently completed Mont Blanc Phase III study for NCX-470 and explains why the drug’s attributes may differentiate it from existing therapies, including its dual mechanism of action. He discusses the company’s strategy to start two new Phase IIIb studies and how the anticipated data points may show additional positive distinctive aspects on the drug’s ability to have a positive effect for the treatment of glaucoma. He then outlines the next steps for NCX-4251 and NCX-1728, as well as upcoming milestones for the company.